Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS)

• DOI: 10.1111/cas.15871
• Publication Date: 2023-07-01T05:42:07Z
• Authors: Shintaro Shiba; Masaru Wakatsuki; Shingo Toyama; Kazuki Terashima; Hirofumi Uchida; Hiroyuki Katoh; Kei Shibuya; Shohei Okazaki; Yuhei Miyasaka; Tatsuya Ohno; Hiroshi Tsuji
• Keywords: Treatment Outcome; Japan; Liver Neoplasms; Radiation Oncology; Humans; Multicenter Studies as Topic; Heavy Ion Radiotherapy; ORIGINAL ARTICLES; Progression-Free Survival; 3. Good health; Retrospective Studies

AbstractReports on the therapeutic efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for oligometastatic liver disease are limited, with insufficient evidence. This study aimed to evaluate the clinical outcomes of C‐ion RT for oligometastatic liver disease at all Japanese facilities using the nationwide cohort data. We reviewed the medical records to obtain the nationwide cohort registry data on C‐ion RT between May 2016 and June 2020. Patients (1) with oligometastatic liver disease as confirmed by histological or diagnostic imaging, (2) with ≤3 synchronous liver metastases at the time of treatment, (3) without active extrahepatic disease, and (4) who received C‐ion RT for all metastatic regions with curative intent were included in this study. C‐ion RT was performed with 58.0–76.0 Gy (relative biological effectiveness [RBE]) in 1–20 fractions. In total, 102 patients (121 tumors) were enrolled in this study. The median follow‐up duration for all patients was 19.0 months. The median tumor size was 27 mm. The 1‐year/2‐year overall survival, local control, and progression‐free survival rates were 85.1%/72.8%, 90.5%/78.0%, and 48.3%/27.1%, respectively. No patient developed grade 3 or higher acute or late toxicity. C‐ion RT is a safe and effective treatment for oligometastatic liver disease and may be beneficial as a local treatment option in multidisciplinary treatment.